Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.
Howell J, Pinato DJ, Ramaswami R, Arizumi T, Ferrari C, Gibbin A, Burlone ME, Guaschino G, Toniutto P, Black J, Sellers L, Kudo M, Pirisi M, Sharma R. Howell J, et al. Among authors: arizumi t. Oncotarget. 2017 May 30;8(22):36161-36170. doi: 10.18632/oncotarget.15322. Oncotarget. 2017. PMID: 28212535 Free PMC article.
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
Howell J, Pinato DJ, Ramaswami R, Bettinger D, Arizumi T, Ferrari C, Yen C, Gibbin A, Burlone ME, Guaschino G, Sellers L, Black J, Pirisi M, Kudo M, Thimme R, Park JW, Sharma R. Howell J, et al. Among authors: arizumi t. Aliment Pharmacol Ther. 2017 Apr;45(8):1146-1155. doi: 10.1111/apt.13977. Epub 2017 Mar 2. Aliment Pharmacol Ther. 2017. PMID: 28252185 Free article.
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study.
Pinato DJ, Arizumi T, Jang JW, Allara E, Suppiah PI, Smirne C, Tait P, Pai M, Grossi G, Kim YW, Pirisi M, Kudo M, Sharma R. Pinato DJ, et al. Among authors: arizumi t. Oncotarget. 2016 Jul 12;7(28):44705-44718. doi: 10.18632/oncotarget.9604. Oncotarget. 2016. PMID: 27244889 Free PMC article.
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.
Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, Kudo M, Howell J, Ramaswami R, Burlone ME, Guerra V, Thimme R, Ishizuka M, Stebbing J, Pirisi M, Carr BI. Pinato DJ, et al. Among authors: arizumi t. J Hepatol. 2017 Feb;66(2):338-346. doi: 10.1016/j.jhep.2016.09.008. Epub 2016 Sep 24. J Hepatol. 2017. PMID: 27677714 Free article.
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study.
Yen C, Sharma R, Rimassa L, Arizumi T, Bettinger D, Choo HY, Pressiani T, Burlone ME, Pirisi M, Giordano L, Abdulrahman A, Kudo M, Thimme R, Park JW, Pinato DJ. Yen C, et al. Among authors: arizumi t. Liver Cancer. 2017 Nov;6(4):313-324. doi: 10.1159/000480441. Epub 2017 Sep 16. Liver Cancer. 2017. PMID: 29234635 Free PMC article.
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.
Hajiev S, Allara E, Motedayеn Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, Kudo M, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R. Hajiev S, et al. Among authors: arizumi t. Br J Cancer. 2021 Jan;124(2):407-413. doi: 10.1038/s41416-020-01116-9. Epub 2020 Oct 19. Br J Cancer. 2021. PMID: 33071284 Free PMC article.
124 results